StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
VSTMBullishIndustry Newsnews
High materiality8/10

Verastem’s KRAS G12D Inhibitor VS-7375 Advances with TARGET-D 202 NSCLC Dosing

Jul 22, 2026, 4:06 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Near-term catalysts (first-patient dosing in TARGET-D 202, Fast Track designations) could drive upside if data show meaningful activity; however, failure risks remain high given early-stage data and KRAS G12D challenges.

AI summary

What happened, with direct paths to the underlying reporting

Verastem Oncology announced the first patient dosing in TARGET-D 2022 (TARGET-D 202) evaluating VS-7375 at the 900 mg daily RP2D for KRAS G12D-mutated NSCLC, including a cohort with untreated brain metastases. The program aims to establish a registration-directed path across multiple KRAS G12D tumor types, with data updates anticipated in the second half of 2026 and Fast Track support potentially accelerating development.

  • First patient dosed in TARGET-D 202 NSCLC; RP2D 900 mg daily.
  • TARGET-D 202 includes brain metastases cohort in untreated NSCLC.
  • KRAS G12D NSCLC ~5% of NSCLC; no FDA-approved G12D therapies.
  • VS-7375 is a dual ON/OFF KRAS G12D inhibitor; 3 TARGET-D trials advancing; update H2 2026.
  • FDA Fast Track designation secured for VS-7375 in pancreatic cancer and NSCLC.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event